Saroglitazar

Saroglitazar Mg: A Potent and Selective Peroxisome Proliferator-activated Receptor Alpha and Gamma Dual Agonist - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 16, 2021
Health, Pharmaceutical, Branches of biology, Carboxylic acids, Transcription factors, Intracellular receptors, Cell biology, Chemistry, Peroxisome proliferator-activated receptor alpha, Saroglitazar, Peroxisome proliferator-activated receptor, PPARGC1B, Alpha agonist

The "Saroglitazar Mg - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Saroglitazar Mg - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • SAROGLITAZAR Mg is a potent and selective peroxisome proliferator-activated receptor alpha and gamma dual agonist.
  • "SAROGLITAZAR Mg - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Primary Biliary Cirrhosis in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

Galmed Pharmaceuticals to Present New Data on Aramchol Effect on Glucose Metabolism, MoA and Clinical Results at AASLD 2019

Retrieved on: 
Thursday, October 31, 2019
Medicine, Clinical medicine, Diabetes, Endocrine diseases, Blood tests, Glucose, Glycated hemoglobin, Hemoglobins, Gemigliptin, Saroglitazar

This new pre-clinical data elucidates the mechanism by which Aramchol affects glucose metabolism in the liver that resulted in a reduction of HbA1C in patients in the Company's Phase IIb trial.

Key Points: 
  • This new pre-clinical data elucidates the mechanism by which Aramchol affects glucose metabolism in the liver that resulted in a reduction of HbA1C in patients in the Company's Phase IIb trial.
  • The data suggests that Aramchol improves liver glucose homeostasis in patients and murine models.
  • Galmed will also present clinical data on the rationale for the Phase 3/4 dose selection and its potential increased efficacy.
  • "In addition, the clinical data we are presenting demonstrated a significant increase in exposure following twice daily treatment, potentially increasing efficacy."